Search Results - Yi‐Long Wu

Refine Results
  1. 1
    Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

    Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China by Yi‐Long Wu, Lan-ying Gou

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Immunotherapy in the Asiatic population: any differences from Caucasian population?

    Immunotherapy in the Asiatic population: any differences from Caucasian population? by Lun-Xi Peng, Yi‐Long Wu

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

    Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China by Si‐Yang Maggie Liu, Yi‐Long Wu

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)

    Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) by Si‐Yang Maggie Liu, Yi‐Long Wu

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancer

    The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancer by Wen‐Zhao Zhong, Qing Zhou, Yi‐Long Wu

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

    The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer by Yi-Chen Zhang, Qing Zhou, Yi‐Long Wu

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Overcoming immune evasion with innovative multi-target approaches for glioblastoma

    Overcoming immune evasion with innovative multi-target approaches for glioblastoma by Hai Su, Peng Yin, Yi‐Long Wu, Xiaoli Zeng

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

    Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) by Simon Dearden, James Stevens, Yi‐Long Wu, David P. Blowers

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Differences in driver genes between smoking‐related and non–smoking‐related lung cancer in the Chinese population

    Differences in driver genes between smoking‐related and non–smoking‐related lung cancer in the Chinese population by Lan-ying Gou, Feiyu Niu, Yi‐Long Wu, Wen‐Zhao Zhong

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Emerging therapies for non-small cell lung cancer

    Emerging therapies for non-small cell lung cancer by Chao Zhang, Natasha B. Leighl, Yi‐Long Wu, Wen‐Zhao Zhong

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer

    LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer by Zhongbao Zhang, Jiajing Cheng, Yi‐Long Wu, Jin Qiu, Yi Sun, Xiaowen Tong

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection by Yi‐Long Wu, Roy S. Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti, Masahiro Tsuboi

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042

    195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042 by Tony Mok, Yi‐Long Wu, S. Sadowski, J. Zhang, Reshma Rangwala, Debra Kush, Gilberto Lopes

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)

    P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894) by Gilberto Lopes, Yi‐Long Wu, S. Sadowski, Jin Zhang, Reshma Rangwala, Debra Kush, Tony Mok

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Influence of Curcumin on HOTAIR-Mediated Migration of Human Renal Cell Carcinoma Cells

    Influence of Curcumin on HOTAIR-Mediated Migration of Human Renal Cell Carcinoma Cells by Chang-Song Pei, Hongyan Wu, Fan-Tian Fan, Yi‐Long Wu, Cunsi Shen, Liqun Pan

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer

    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer by Wen‐Zhao Zhong, Xue‐Ning Yang, Jianling Bai, Jin‐Ji Yang, Christian Manegold, Yi‐Long Wu

    Published 2008
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  17. 17
    Multiple primary malignancies involving lung cancer

    Multiple primary malignancies involving lung cancer by Feng Li, Wen‐Zhao Zhong, Feiyu Niu, Ning Zhao, Jin‐Ji Yang, Hong‐Hong Yan, Yi‐Long Wu

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy by Bruno Coudert, Tudor‐Eliade Ciuleanu, K. Park, Yi‐Long Wu, Giuseppe Giaccone, Wolfram Brugger, P. Gopalakrishna, Federico Cappuzzo

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)

    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IU... by Saulius Cicėnas, Sarayut Lucien Geater, Petar Petrov, Yevhen Hotko, Gregory Hooper, Fan Xia, Nadejda Mudie, Yi‐Long Wu

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Emerging evidence and treatment paradigm of non-small cell lung cancer

    Emerging evidence and treatment paradigm of non-small cell lung cancer by Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si‐Yang Maggie Liu, Yangqiu Li, Yi‐Long Wu

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: